Roche launched the cobas eplex respiratory pathogen panel 3 (RP3), a diagnostic test that detects up to 250 viruses and bacteria, including SARS-CoV-2 and influenza, from a single patient sample. The test provides rapid results, enabling doctors to quickly identify the cause of respiratory infections and make timely treatment decisions, especially for high-risk patients. Designed for ease of use on the cobas eplex system, it helps hospitals manage respiratory case surges and improve patient care by reducing unnecessary antibiotic use and optimizing isolation protocols. The test is now available in countries accepting the CE mark and offers customizable panels to address local infection patterns.
Lowey Dannenberg, P.C. is investigating Hims & Hers Health, Inc. for allegedly sharing sensitive user health data, including medical histories and mental health info, with third parties without proper consent. This raises concerns about violations of...
Digital agency 9thCO completed a major digital transformation for DNRS, moving from a fragmented WordPress setup to a unified composable architecture. This upgrade centralizes user management, integrates key business tools like CRM and scheduling, an...
Willis Towers Watson, a global advisory firm, is poised for growth with a 25.3% potential stock upside, driven by new initiatives like KwantSure, a digital insurance sales channel for subcontractors, and a Geospatial Mortality Model to improve pensio...
AngioDynamics reported an 8% revenue increase to $86.6 million in Q4, driven by a 16.7% sales rise in its Med Tech division, notably from NanoKnife and AlphaVac products. H.C. Wainwright raised the price target from $16 to $19 and maintained a Buy ra...
PNC Financial Services Group reported Q2 2026 adjusted EPS of $4.85 and record revenue of $6.88 billion, surpassing analyst expectations. The growth was driven by a 15.5% rise in net interest income and a 31.4% increase in fee income, reflecting stro...
